• Something wrong with this record ?

Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study

YS. Rho, M. Gilabert, K. Polom, A. Aladashvili, K. Kopeckova, V. Megdanova, N. Coleman, M. Greally, D. Marrelli, F. Roviello, R. McDermott, V. Petrova, Z. Mihaylova, Z. Bortlicek, J. Prausova, G. Batist, L. Azoulay, P. Kavan,

. 2017 ; 16 (4) : 334-342. [pub] 20170321

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18033915

BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled. Patients were randomly chosen from each center's database, and the patient demographics and treatment information were collected. The data were then centralized, and the final analysis was performed at a single institution. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival and mortality, and YO was compared with LO. Site-specific HRs were pooled using a random-effects meta-analysis. RESULTS: Overall, 498 patients, including 224 with YO (129 men; mean age, 37 ± 5.5 years) and 274 with LO (167 men; mean age, 64.8 ± 9.5 years) CRC, were included. At the diagnosis, 137 patients (61.2%) and 122 patients (44.5%) with YO and LO CRC had metastatic disease, respectively. For both cohorts, the 3 most common presenting symptoms were pain, hematochezia, and weight loss. Surgery was performed in 141 YO (63.0%) and 219 LO (79.9%) patients. The longitudinal noncurative treatment patterns were similar, but more biologic therapy was used for these YO patients. The pooled progression-free survival analysis results for first-line noncurative treatment favored LO (HR, 1.96; 95% CI, 1.04-3.68). The mortality analysis showed no significant differences between the 2 groups (YO: HR, 1.53; 95% CI, 0.91-2.58). CONCLUSION: Despite similar treatment patterns and survival outcomes, YO disease might be clinically more aggressive.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033915
003      
CZ-PrNML
005      
20181023110047.0
007      
ta
008      
181008s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clcc.2017.03.008 $2 doi
035    __
$a (PubMed)28462853
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rho, Young Soo $u Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada.
245    10
$a Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study / $c YS. Rho, M. Gilabert, K. Polom, A. Aladashvili, K. Kopeckova, V. Megdanova, N. Coleman, M. Greally, D. Marrelli, F. Roviello, R. McDermott, V. Petrova, Z. Mihaylova, Z. Bortlicek, J. Prausova, G. Batist, L. Azoulay, P. Kavan,
520    9_
$a BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled. Patients were randomly chosen from each center's database, and the patient demographics and treatment information were collected. The data were then centralized, and the final analysis was performed at a single institution. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival and mortality, and YO was compared with LO. Site-specific HRs were pooled using a random-effects meta-analysis. RESULTS: Overall, 498 patients, including 224 with YO (129 men; mean age, 37 ± 5.5 years) and 274 with LO (167 men; mean age, 64.8 ± 9.5 years) CRC, were included. At the diagnosis, 137 patients (61.2%) and 122 patients (44.5%) with YO and LO CRC had metastatic disease, respectively. For both cohorts, the 3 most common presenting symptoms were pain, hematochezia, and weight loss. Surgery was performed in 141 YO (63.0%) and 219 LO (79.9%) patients. The longitudinal noncurative treatment patterns were similar, but more biologic therapy was used for these YO patients. The pooled progression-free survival analysis results for first-line noncurative treatment favored LO (HR, 1.96; 95% CI, 1.04-3.68). The mortality analysis showed no significant differences between the 2 groups (YO: HR, 1.53; 95% CI, 0.91-2.58). CONCLUSION: Despite similar treatment patterns and survival outcomes, YO disease might be clinically more aggressive.
650    _2
$a adenokarcinom $x epidemiologie $x patologie $x terapie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologická terapie $x metody $7 D001691
650    _2
$a kolorektální nádory $x epidemiologie $x patologie $x terapie $7 D015179
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Gilabert, Marine $u Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
700    1_
$a Polom, Karol $u General and Oncological Surgery Department, University of Siena, Siena, Italy.
700    1_
$a Aladashvili, Archil $u GI Cancer Research Unit and Oncology Surgery, National Cancer Center, Tbilisi, Georgia.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine-Charles University Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Megdanova, Vera $u Department of Medical Oncology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Coleman, Niamh $u Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.
700    1_
$a Greally, Megan $u Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.
700    1_
$a Marrelli, Daniele $u General and Oncological Surgery Department, University of Siena, Siena, Italy.
700    1_
$a Roviello, Franco $u General and Oncological Surgery Department, University of Siena, Siena, Italy.
700    1_
$a McDermott, Ray $u Department of Medical Oncology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Petrova, Veneta $u Department of Medical Oncology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Mihaylova, Zhasmina $u Department of Medical Oncology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Prausova, Jana $u Department of Oncology, Second Faculty of Medicine-Charles University Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Batist, Gerald $u Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada.
700    1_
$a Azoulay, Laurent $u Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
700    1_
$a Kavan, Petr $u Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada. Electronic address: petr.kavan@mcgill.ca.
773    0_
$w MED00007435 $t Clinical colorectal cancer $x 1938-0674 $g Roč. 16, č. 4 (2017), s. 334-342
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28462853 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181023110554 $b ABA008
999    __
$a ok $b bmc $g 1339655 $s 1030909
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 16 $c 4 $d 334-342 $e 20170321 $i 1938-0674 $m Clinical colorectal cancer $n Clin Colorectal Cancer $x MED00007435
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options